SCHEMBL286026

SCHEMBL286026

CCCCc1noc(C)c1C(O)Cc1nc(C)c(C(=O)OC)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
RAB9A P51151 5/20 0.35
KDM4E B2RXH2 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
HSD17B10 Q99714 2/20 0.35
TSHR P16473 2/20 0.34
NPC1 O15118 4/20 0.34
NPSR1 Q6W5P4 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HPGD P15428 4/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
MAPT P10636 1/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285975 0.82 ALDH1A1 (0.35) RAB9AKDM4ESMN1; SMN2NPC1HPGD
SCHEMBL285984 0.82 POLB (0.43) POLBRAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL286434 0.78 LMNA (0.46) POLBRAB9AKDM4ESMN1; SMN2TSHR
SCHEMBL285901 0.77 POLB (0.42) POLBRAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL285902 0.77 POLB (0.42) POLBRAB9AKDM4ESMN1; SMN2HSD17B10
SCHEMBL286082 0.71 KMT2A (0.41) POLBTSHRKMT2AALDH1A1L3MBTL1
SCHEMBL285588 0.71 KMT2A (0.41) POLBTSHRKMT2AALDH1A1L3MBTL1
SCHEMBL286243 0.71 KMT2A (0.41) POLBTSHRKMT2AALDH1A1L3MBTL1
SCHEMBL286186 0.71 L3MBTL1 (0.37) POLBKDM4EALDH1A1L3MBTL1LMNA
SCHEMBL285936 0.70 L3MBTL1 (0.32) POLBTSHRKMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427459-B1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN LA ROCHE (CH) 2016-09-28 EP disclosed
US-8178522-B2 Thiazoles HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010127974-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286116-A1 THIAZOLES ROCHE PALO ALTO LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286116-A1 THIAZOLES GABRA5, GABRA1, GABRA4 POLB 4094/4885RAB9A 2227/4885KDM4E 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.